Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer

被引：0
|
作者：
Aredo, J. [1 ]
Padda, S. [1 ]
Kunder, C. [2 ]
Han, S. [1 ]
Wakelee, H. [1 ]
机构：
[1] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期
关键词：
KRAS; Non-small cell lung cancer; disparities; Immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA03.07
引用
收藏
页码：S1133 / S1133
页数：1
相关论文
共 50 条
  • [41] Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer
    Metro, Giulio
    Chiari, Rita
    Baldi, Alice
    De Angelis, Verena
    Minotti, Vincenzo
    Crino, Lucio
    [J]. FUTURE ONCOLOGY, 2013, 9 (02) : 167 - 177
  • [42] Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?
    Karim, Nagla Abdel
    Ullah, Asad
    Pathrose, Peterson
    Fathallah, Hassana
    Perry, Ashley
    Morris, John C.
    Wang, Jiang
    Starnes, Sandra L.
    [J]. CURRENT ONCOLOGY, 2022, 29 (07) : 4779 - 4790
  • [43] Molecular mechanisms driving oncogenesis in KRAS mutant non-small cell lung cancer
    Holderfield, Matthew
    McCormick, Frank
    Nagel, Tobi
    [J]. CANCER RESEARCH, 2010, 70
  • [44] The role of EphA2 in KRAS mutant non-small cell lung cancer
    Amato, Katherine
    Wang, Shan
    Hastings, Andrew
    Chen, Haiying
    Colvin, Daniel
    Ye, Fei
    Chen, Jin
    [J]. MOLECULAR CANCER RESEARCH, 2014, 12
  • [45] Molecular Characterization and Prognosis of Patients with KRAS Mutant Non-small Cell Lung Cancer
    Gutierrez Sainz, L.
    Villamayor, J.
    Higuera, O.
    Cruz Castellanos, P.
    Vinal Lozano, D.
    Esteban Rodriguez, I.
    Regojo, R. M.
    Pelaez Garcia, A.
    Heredia Soto, V.
    Mendiola, M.
    Rosas Alonso, R.
    Rodriguez Antolin, C.
    Ibanez de Caceres, I.
    de Castro Carpeno, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S620 - S621
  • [46] A role of nicotinamide phosphoribosyltransferase in growth of KRAS mutant non-small cell lung cancer
    Okumura, Shunsuke
    Sasaki, Takaaki
    Ohsaki, Yoshinobu
    [J]. CANCER RESEARCH, 2015, 75
  • [47] Mutant KRAS decouples glycolysis from cell mechanics in non-small cell lung cancer
    Park, Jin Suk
    Sudderth, Jessica
    Gao, Boning
    Bachoo, Robert
    Danuser, Gaudenz
    [J]. CANCER RESEARCH, 2017, 77
  • [48] Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review
    Santarpia, Mariacarmela
    Ciappina, Giuliana
    Spagnolo, Calogera Claudia
    Squeri, Andrea
    Passalacqua, Maria Ilenia
    Aguilar, Andres
    Gonzalez-Cao, Maria
    Giovannetti, Elisa
    Silvestris, Nicola
    Rosell, Rafael
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 346 - 368
  • [49] Poor therapeutic outcomes in KRAS-mutant non-small cell lung cancer due to chemoresistance conferred by SLC7A11
    Zhang, Shiyu
    Ge, Yutong
    Liu, Jingwen
    Lu, Kaihua
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [50] A novel ERK1/2 inhibitor has potent activity in KRAS-mutant non-small cell lung cancer models
    Courtin, Aurelie
    Bevan, Luke
    Heightman, Tom
    Kidane, Birikiti
    Kucia-Tran, Justyna
    Lyons, John
    Muench, Sandra
    Shah, Alpesh
    Stanczuk, Lukas
    Thompson, Neil
    Wallis, Nicola
    Wilsher, Nicola
    Munck, Joanne
    [J]. CANCER RESEARCH, 2018, 78 (13)
12345